New synthetic antagonists of bradykinin.

Br J Pharmacol

Department of Physiology, University of Alberta, Edmonton, Canada.

Published: December 1987

1 A new synthetic bradykinin analogue was found to be an antagonist of bradykinin-induced vascular permeability in rabbit skin. It was effective in equimolar concentrations. 2 These analogues also antagonized the action of bradykinin in contracting the guinea-pig isolated ileum. The mean pA2 values of five different antagonists ranged from 5.3-6.4 respectively, on this preparation. 3 Our observations, together with those of others suggest that these antagonists act on the same receptor types, viz., B2, in rabbit blood vessels and in smooth muscle of guinea-pig ileum. 4 Our results support the view that the way is now promising for the synthesis of potent specific antagonists of bradykinin for experimental and therapeutic use.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1853719PMC
http://dx.doi.org/10.1111/j.1476-5381.1987.tb11390.xDOI Listing

Publication Analysis

Top Keywords

antagonists bradykinin
8
synthetic antagonists
4
bradykinin
4
bradykinin synthetic
4
synthetic bradykinin
4
bradykinin analogue
4
analogue antagonist
4
antagonist bradykinin-induced
4
bradykinin-induced vascular
4
vascular permeability
4

Similar Publications

The amphibian skin secretions are excellent sources of bioactive peptides, some of which and their derivatives exhibit multiple properties, including antibacterial and antagonism against bradykinin. A novel peptide Senegalin-2 was isolated from the skin secretions of frog. Senegalin-2 relaxed rat bladder smooth muscle (EC 17.

View Article and Find Full Text PDF

The role of the dorsomedial hypothalamus in the cardiogenic sympathetic reflex in the Sprague Dawley rat.

Front Physiol

December 2024

Biomedical Science Department, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, United States.

Myocardial ischemia causes the production and release of metabolites such as bradykinin, which stimulates cardiac spinal sensory afferents, causing chest pain and an increase in sympathetic activity referred to as the cardiogenic sympathetic afferent reflex. While the brain stem nuclei, such as the nucleus tractus solitarius and rostral ventrolateral medulla, are essential in the cardiogenic sympathetic afferent reflex, the role of other supramedullary nuclei in the cardiogenic sympathetic afferent reflex are not clear. The dorsomedial hypothalamic nucleus (DMH) is involved in cardiovascular sympathetic regulation and plays an important role in the sympathetic response to stressful stimuli.

View Article and Find Full Text PDF

The plaques associated with Alzheimer's disease are formed as a result of the aggregation of Aβ peptides, which vary in length from 38 to 43 amino acids. The 1-40 peptide is the most abundant, while the 1-42 peptide appears to be the most destructive to neurons and/or glial cells in a variety of assays. We have demonstrated that aggregated Aβ, a state prior to plaque formation, will activate the plasma bradykinin-forming pathway when tested in vitro.

View Article and Find Full Text PDF
Article Synopsis
  • SARS-CoV-2 can infect liver cells (hepatocytes), leading to elevated liver enzymes and more severe disease in those with pre-existing liver conditions.
  • The study shows that the virus replicates and spreads in hepatocytes, with infection being dependent on two specific proteins, ACE2 and TMPRSS2, which are found on the liver cells.
  • Infection causes rapid liver cell death, with the Omicron variant causing quicker but less extensive damage compared to other strains, as seen in both human liver cells and infected mice.
View Article and Find Full Text PDF

Over the past 2 decades, guidelines for the on-demand treatment of hereditary angioedema attacks have undergone significant evolution. Early treatment guidelines, such as the Canadian 2003 International Consensus Algorithm, often gated on-demand treatment by attack location and/or severity. Pivotal trials for on-demand injectable treatments (plasma-derived C1 esterase inhibitor, icatibant, ecallantide [United States only], and recombinant human C1 esterase inhibitor), which were approved in the United States and the European Union between 2008 and 2014, were designed accordingly.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!